Switching antipsychotics to support the physical health of people with severe mental illness: a qualitative study of healthcare professionals' perspectives by Nash, A et al.
1Nash A, et al. BMJ Open 2021;11:e042497. doi:10.1136/bmjopen-2020-042497
Open access 
Switching antipsychotics to support the 
physical health of people with severe 
mental illness: a qualitative study of 
healthcare professionals’ perspectives
Annabel Nash,1,2 Tom Kingstone   ,1,3 Saeed Farooq,1,3 Jessica Tunmore,1,3 
Carolyn A Chew- Graham1,3
To cite: Nash A, Kingstone T, 
Farooq S, et al.  Switching 
antipsychotics to support 
the physical health of 
people with severe mental 
illness: a qualitative study 
of healthcare professionals’ 
perspectives. BMJ Open 
2021;11:e042497. doi:10.1136/
bmjopen-2020-042497
 ► Prepublication history and 
supplemental material for this 
paper is available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2020- 
042497).
Received 06 July 2020
Revised 22 January 2021
Accepted 08 February 2021
1Research and Innovation 
Department, Midlands 
Partnership NHS Foundation 
Trust, Stafford, UK
2School of Life Sciences 
and Education, Staffordshire 
University, Stoke- on- Trent, UK
3School of Medicine, Keele 
University, Keele, UK
Correspondence to
Dr Tom Kingstone;  
 t. kingstone@ keele. ac. uk
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Objectives The side effects of antipsychotic medications 
(APs) can increase the risk of developing physical health 
conditions. Some APs pose a higher risk than others. 
Evidence suggests switching to lower risk APs can support 
physical health outcomes. We sought to explore the views 
of healthcare professionals about switching antipsychotics 
to support physical health in people with severe mental 
illness (SMI).
Design A qualitative study with semi- structured 
interviews conducted with general practitioners (GPs), 
psychiatrists and mental health nurses. The main focus 
was to explore participants’ views on the physical health 
of people with SMI, the impact of APs and decision- making 
about switching medication to support physical health. 
Data were analysed thematically using principles of 
constant comparison.
Settings Participants recruited through primary care and 
one mental health trust in the West Midlands.
Participants Interviews were conducted with 9 GPs, 10 
psychiatrists and 4 mental health nurses.
Results Awareness and knowledge of AP side- effects 
and risk profiles varied considerably between primary 
and secondary care clinicians. GPs reported limited 
awareness, while psychiatrists and nurses demonstrated 
a comprehensive understanding of AP risk profiles and 
side- effects. Mental health and control of symptoms were 
prioritised. Switching to promote physical health was 
considered as a reactive intervention, once side- effects 
or complications developed. There were a range of views 
over where responsibility lay for monitoring physical health 
and consideration of switching. Collaboration between 
primary and secondary care was identified as a way to 
address this.
Conclusions This study presents multidisciplinary 
perspectives on awareness, decision making, perceived 
responsibility and barriers to switching APs to support 
physical health. Collaborative approaches that involve 
liaison between primary and secondary care, but tailored 
to the individual patient, may support switching, and 
present an opportunity to intervene to address the 
physical health inequalities experienced by individuals 
with SMI.
INTRODUCTION
The life expectancy for people with severe 
mental illness (SMI) is reduced on average by 
15–20 years compared with the general popu-
lation.1 This mortality gap is widening2 and 
continues to be driven by high suicide rates 
and comorbid physical health problems such 
as cardiovascular disease (CVD) and diabetes. 
Individuals with SMI are twice as likely to 
develop type 2 diabetes compared with the 
general population.3 Poor socioeconomic 
conditions and lifestyle choices contribute 
to the increased risk of CVD and diabetes.4–6 
The National Health Service (NHS) Five 
Year Forward View stresses the importance of 
meeting the physical health needs of people 
with SMI to reduce mortality rates.7 To 
achieve this, we must understand the modi-
fiable factors contributing to this inequality.
Lifestyle factors including poor diet, phys-
ical inactivity, smoking and substance misuse 
contribute to increased cardiometabolic risk. 
Strengths and limitations of this study
 ► This study addresses a gap in the literature by using 
qualitative methods to provide an in- depth explora-
tion of healthcare professionals’ (HCPs) views and 
experiences of switching.
 ► This study explores the perspectives of HCPs from 
three disciplines (general practice, nursing and psy-
chiatry) to provide a holistic account of perspectives 
on switching.
 ► Patients and carers contributed to the study design 
and interpretation of findings.
 ► Only 4 mental health nurses from the 53 invited to 
participate were interviewed which meant data sat-
uration was not achieved for this group. The trans-
ferability of the findings to other settings may be 
restricted due to sampling psychiatrists and mental 
health nurses from one mental health trust; a more 
diverse sample, from a range of trusts, might have 
uncovered different perspectives.
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However, trials of lifestyle interventions including individ-
uals with SMI prescribed antipsychotic medications (APs) 
have been largely ineffective, both in terms of improving 
physical health outcomes and cost- effectiveness.8 9 APs 
can cause increased appetite, weight gain and insulin 
resistance, all of which increase the risk of metabolic 
syndrome and contribute to increased morbidity and 
mortality. Evidence suggests a holistic approach to inter-
vention which addresses the multiple contextual factors 
impacting upon the physical health of individuals with 
SMI is required.10
Meta- analyses have shown small differences in effective-
ness in managing symptoms of psychosis between APs, 
but significant differences in metabolic side- effects.11–13 
Considering some of the most commonly prescribed 
second- generation APs,14 clozapine and olanzapine have 
the highest propensity to cause weight gain and meta-
bolic abnormalities, quetiapine, followed by risperidone 
have a moderate metabolic risk. In contrast, aripiprazole 
and lurasidone have the smallest impact on metabolic 
profiles.11–13 A systematic review reported that switching 
from olanzapine to aripiprazole was associated with weight 
loss and improved glucose and lipid profiles; no signifi-
cant differences in mental state were reported for those 
who switched, suggesting an overall benefit of switching. 
However, methodological limitations were noted in the 
studies reviewed.15 Guidelines recommend considering a 
switch of AP as a treatment option to improve physical 
health.10 However, this rarely happens in clinical practice.
The National Institute for Health and Care Excellence 
recommends that APs for people with SMI should be 
initiated in specialist care.16 Primary care is responsible 
for conducting screening and physical health interven-
tions for people with SMI on general practitioner (GP) 
registers.17 Over half of people with SMI on a GP list are 
looked after solely by the practice, without any specialist 
care input.
Switching of APs could feasibly take place in primary 
or specialist care. No research has previously explored 
whether and/or how switching APs to improve physical 
health in people with SMI is considered or carried out in 
clinical practice. Our qualitative study aimed to address 
this gap by exploring healthcare professionals’ (HCPs) 
views on the barriers and facilitators to switching APs.
METHODS
Design and setting
A qualitative study in which semi- structured interviews 
were conducted with HCPs (GPs, psychiatrists and mental 
health nurses) to explore their views on switching APs 
to support physical health outcomes for people with 
SMI. This method supported an in- depth exploration of 
experiences in this underexplored area.18 The study was 
conducted in primary and secondary care in the West 
Midlands and North West of England, in urban, semi- rural 
and rural areas. The ‘Consolidated criteria for Reporting 
Qualitative research’ checklist was used to ensure rigour 
of analysis and credibility of findings.19
Participants and recruitment
Purposive sampling guided recruitment. Inclusion criteria 
were broad to include a diverse range of experiences from 
HCPs involved in prescribing APs to individuals with SMI. 
See online supplemental file 1 for an overview of HCP 
roles. GP practices across the West Midlands and North 
West of England were contacted. Psychiatrists and mental 
health nurses were identified through Midlands Partner-
ship NHS Foundation Trust (MPFT). Study information 
was shared by email via existing contacts within the team, 
GP practice managers, and with staff in the Psychosis Path-
ways and Early Intervention Teams at MPFT. Sixteen GP 
practices, 21 psychiatrists and 53 nurses were contacted. 
As GPs are self- employed, they were offered reimburse-
ment of £80 per hour (British Medical Association rates).
Data collection
A flexible topic guide (box 1) was developed using 
existing literature, the teams’ clinical experience and 
with a patient and public involvement and engagement 
(PPIE) group.
All interviews were completed by AN (female research 
assistant, with qualitative research expertise) between 
January and August 2019. After two pilot interviews, 
the topic guide and interviews were discussed by AN 
and CAC- G. Following discussion in the team, the topic 
guide was modified iteratively as data were collected and 
analysed to facilitate further exploration of key themes. 
Prompts were added to explore: communication and 
responsibility between primary and secondary care, HCPs 
comfort with switching and patient’s requests to switch. 
Box 1 Topic guide summary
Experiences of prescribing antipsychotics
 ► Prescribing experience.
 ► Factors considered when prescribing.
 ► Information shared with patients.
 ► Physical health monitoring.
 ► Patient- led reduction/switching/withdrawal of APs.
This section was adapted for non- prescribing nurses to explore their 
role in supporting the prescribing of APs.
Experiences of and views on switching antipsychotics
 ► Current practice.
 ► Experiences of switching.
 ► Reasons for switching.
 ► When to consider switching.
 ► Views on and comfort when switching.
 ► Patient’s responses.
 ► Barriers and facilitators to switching to improve physical health.
This section was adapted for non- prescribing nurses to explore their 
experience of support with switching APs.
Other interventions and support to promote physical health
 ► What other interventions are important.
 ► Involvement of patient’s support networks.
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The majority of interviews were conducted face- to- face at 
the participant’s place of work; one was completed by tele-
phone. No repeat interviews were conducted. Informed 
consent was obtained prior to interviews, which were 
audio recorded and transcribed verbatim by an external 
transcription company or AN. Transcripts were anony-
mised and labelled with a unique participant identifier. 
The transcripts were not returned to participants for 
checking due to time constraints, however participants 
could withdraw data up to 2 weeks after the interview.
Data collection and analysis were conducted concur-
rently, informed by inductive thematic saturation and 
ended when no new codes or themes were identified.20 
AN kept field notes that were discussed in research team 
meetings.
Data analysis
A thematic analysis was applied, led by the first author.21 
AN read, re- read and coded all transcripts manually to 
identify key codes and preliminary themes. CAC- G and 
SF analysed a selection of the transcripts. The team drew 
upon clinical experiences to inform interpretations of 
the data. Preliminary themes were discussed during team 
meetings to explore similar and differing interpreta-
tions of the data before collaboratively agreeing the key 
themes. Constant comparison was used to analyse simi-
larities and differences between participants’ accounts to 
ensure themes captured different perspectives.22
Patient and public involvement
A McPin Foundation PPIE group contributed to topic 
guide development. Members of the Patient and Carer 
Involvement in Research group at MPFT reviewed prelim-
inary analysis and contributed their interpretations of 
data presented.
RESULTS
Interviews were conducted with 9 GPs, 10 psychiatrists 
and 4 mental health nurses. Demographic characteristics 
of the participants are reported in table 1.
Interviews ranged in duration from 44 min to 85 min.
Five main themes were identified as follows: (1) priority 
given to mental health; (2) contrasting knowledge of 
antipsychotic medication (AP) risk profiles; (3) switching 
APs as a reactive intervention; (4) whose responsibility? 
and (5) the way forward: a collaborative approach. Each 
theme is described with illustrative data extracts, which 
include identifiers (GP, general practitioner; NU, mental 
health nurse; PS, psychiatrist).
Priority given to mental health
HCPs described the challenge of balancing the mental 
versus physical health needs of an individual. Indeed, 
some HCPs felt they were faced with an absolute choice:
I think it’s which is the best of the two evils…you know 
is it, is it better that they’ve got some physical health 
problems but their mental health is so much better, 
and they can live their life and get a better quality of 
life, or is it better that they have no physical health 
problems and their mental health is out of control 
and they feel tortured. (NU004)
Mental health was prioritised by most HCPs due to the 
overt risk presented. Physical health risks were consid-
ered longer term, not requiring immediate attention:
We still tend to focus on the disease management first 
and then the illness management, the symptom man-
agement that’s, that’s our priority. I think the… side- 
effects erm are still a second thought. (PS010)
Reflecting this priority, many HCPs described consid-
ering switching APs only to improve mental health not 
physical health:
Table 1 Participants’ characteristics
Participant ID Gender Role Time in role
GP001 Male Salaried GP 28 years
GP002 Male Salaried GP 3 years
GP003 Female GP partner 4 years
GP004 Female Salaried GP 29 years
GP005 Male GP partner 10 years
GP006 Male GP partner 8 years
GP007 Female Salaried GP 9 years
GP008 Female Salaried GP 8 years
GP009 Female Salaried GP 6 months
NU001 Male Community mental 
health nurse
2 years
NU002 Female Community mental 
health nurse
2 years
NU003 Female Community mental 
health nurse
40 years
NU004 Female Community mental 
health nurse
28 years
PS001 Male Consultant 
psychiatrist
3 years
PS002 Male Consultant 
psychiatrist
15 years
PS003 Male Specialty doctor in 
psychiatry
6 years
PS004 Male Consultant 
psychiatrist
22 years
PS005 Male Locum consultant 
psychiatrist
11 years
PS006 Female Specialist doctor 7 years
PS007 Female Specialist doctor 7 years
PS008 Female Specialty trainee 
(ST5)
1 year
PS009 Female Consultant 
psychiatrist
15 years
PS010 Male Consultant 
psychiatrist
15 years
GP, general practitioner; NU, mental health nurse; PS, psychiatrist.
4 Nash A, et al. BMJ Open 2021;11:e042497. doi:10.1136/bmjopen-2020-042497
Open access 
But that’s the impression I get, is that the changing 
in antipsychotics is much more mental health driven 
than, than physical health driven. (GP006)
HCPs described improvements in individual’s mental 
health as a long journey for themselves and patients. 
HCPs reported a reluctance to risk the stability achieved 
and associated improvements in patient’s quality of life, 
relationships and well- being:
Once you’ve established somebody on medication 
that has treated their mental disorder, which has of-
ten taken a while to sort of be resolved and has caused 
lots of difficulties, I think there’s still a tendency for 
us not to want to rock the boat…there’s also a sense 
of relief that you know, we’ve dealt with their mental 
health, it’s been a long journey but it’s happened and 
that then trying to address the physical health can 
seem like an extra sort of challenge which we may 
feel that we don’t want to look at. (PS004)
HCPs suggested patients also prioritise their mental 
health over physical health. HCPs faced a dilemma over 
whether to intervene when they observed deteriorations 
in patients’ physical health, but perceived that patients 
were accepting of this deterioration due to not wanting to 
risk improvements in their mental health:
I think that’s an area that’s problematic is that some-
one who comes to see you that’s putting on weight…
you know maybe getting some mild diabetes as a re-
sult but their mental health is very well controlled…
just because I’m putting on some weight, so what? 
And I’ve got some mild diabetes, so what? I feel great 
you know. This is the best drug that I’ve ever been on 
and I never want to go back to that two years of hell 
you know that I went through to get to this point so… 
it’s a tricky area. (GP006)
Knowledge about AP risk profiles
All HCPs reported an awareness of some of the physical 
health side- effects of APs:
So we know from antipsychotic medication there’s an 
increased risk of cardiovascular disease and diabetes, 
generally weight gain. (GP002)
But most GPs were unaware that certain APs carried 
higher metabolic risk than others:
I wasn’t particularly aware of risk of one antipsychot-
ic more than another in terms of metabolic risk. 
(GP007)
Specialist care HCPs were aware of levels of risk associ-
ated with different APs:
Olanzapine, clozapine, quetiapine, amisulpride 
they all cause weight gain. Risperidone maybe not 
as much as olanzapine. Aripiprazole shouldn’t real-
ly cause weight gain but I’ve seen some people gain 
weight on aripiprazole. And lurasidone is marketed 
as one of those that shouldn’t cause weight gain. 
(PS008)
Medication history, patient’s preference, HCP’s pref-
erence and views on efficacy and Trust formularies were 
the key factors considered during decision- making about 
prescribing lower risk APs:
Olanzapine has got a bit of a tendency of putting 
on weight, but it is still considered as a very effective 
medication, most, amongst all antipsychotic medica-
tion, my personal choice is that frankly that olanzap-
ine is the most effective. (PS003)
Some psychiatrists reported a recent shift in their 
prescribing behaviours towards favouring lower risk APs 
to try and minimise longer- term impacts on physical 
health.
I think it’s changing, my practice is changing so I’m 
much more mindful of the side- effects now than I 
was, not short term but longer term. And I think my 
prescribing is reflecting that. Even if perhaps it takes 
a bit longer for say aripiprazole to become effective 
I’m more patient now in continuing with a drug that 
may not be effective because of that lower risk of side- 
effects. (PS010)
This change in prescribing was noted by mental health 
nurses who reported that more patients on their caseload 
were being prescribed lower risk APs, such as aripiprazole:
I’ve got quite a few people on aripiprazole, which has 
got a very low side- effect profile so that’s quite posi-
tive. (NU004)
However, GPs reported the majority of people with 
psychosis were prescribed high- risk APs.
Quetiapine, but yeah to be fair the other one is olan-
zapine, they’re the ones we see most but we do see 
some risperidone…and then the other one is arip-
iprazole, but very rarely do we see people on that. 
(GP003)
All secondary care HCPs were aware that switching 
from higher metabolic risk APs to lower risk APs could be 
used to address physical health problems; in contrast, the 
majority of GPs were unaware of this:
It’s not something I was particularly aware of [laughs], 
but from this I’m now going to think more about 
whether there may be particular drugs that may be 
better in terms of their metabolic risk profile than 
others. (GP007)
GP prescribing and consideration of switching may 
be influenced by the idea that all APs pose a high meta-
bolic risk and inevitably contribute to physical health 
conditions.
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Switching as a reactive intervention
Many HCPs were unsure at what point to consider switching 
APs to improve physical health. Where switching was 
considered, it was described as a reaction to an emerging 
physical health problem and/or following prompting by 
the patient but rarely as a proactive intervention. Ambi-
guity about how to best use routinely collected physical 
health data to inform and justify a switch, was reported:
At what point should switching be considered? You 
know, is it the point where HBA1C is at a certain lev-
el? Is it the point where they have put on so much 
weight? Is it at the point that some, you know, other 
physical parameters can be measured, resulting in 
yellow or red flags and that’s when switching should 
occur so you don’t wait until they need statins, you do 
it much sooner than that. (PS004)
The development of a new physical health condition 
acted as a key driver to prompt considerations about 
switching:
Once they develop diabetes, we need to look at an 
alternative. (PS006)
However, other HCPs felt that rather than consider 
switching an AP, they would increase or add further medi-
cation for the physical condition:
Is the answer switching? I’ve got to admit that… it’s 
probably not the thing that’s at the top of my list. You 
know if their diabetes has got worse I, as a doctor, 
would probably be more inclined to be going increase 
this dose of your anti- diabetic medication [laughs] 
or we need to add another anti- diabetic medication. 
(GP006)
Lifestyle advice was also considered by most HCPs as 
a first- line intervention for emerging cardiovascular and 
metabolic problems:
I’d probably look at lifestyle interventions because 
some of them have been really stable on their medi-
cation and if there are other things that we can do to 
address difficulties then I normally would say let’s try 
that first and if it doesn’t really work then we can look 
at the medication. (PS008)
Some HCPs described how patients had prompted 
consideration of a switch by raising their concerns about 
their physical health and/or AP side- effects:
I think it was the point that the service user said, ac-
tually ‘I’m, I want to do something about this…’ so if 
they hadn’t said that, I suppose we would sort of no-
tified it but maybe we wouldn’t have been prompted 
to make a change without their erm, sort of prompt. 
(PS004)
Furthermore, some HCPs reported it was only when the 
patient linked physical health changes to APs that a medi-
cation review was considered:
Well if someone’s coming in and saying – this pa-
tient comes in and says ‘I’ve been on this and now 
look, I’ve put like a stone on, what’s going on?’, I’d 
be saying ‘Yeah okay, I agree with you’. I’d write to 
the specialist to say ‘You do realise what’s going on?’ 
(GP001)
Whose responsibility?
APs should be initiated in specialist care and then, once 
the patient’s mental health is stable, primary care may 
take over prescribing.16 However, differing opinions were 
held about clinical roles and responsibilities around 
prescribing.
Secondary care HCPs observed an inconsistent 
approach in primary care, which often depended on 
locality. In some localities, decisions made at commis-
sioning level prevented particular GP practices from 
prescribing APs:
Some of them [GPs] are very good to be honest, they 
do everything and they do the annual health check 
and give written information, they’re excellent. Some 
are like ‘we don’t want to touch it, it’s not our job…’ 
There’s a lot of reluctance from some of them. I think 
cost is also a factor for them. (PS009)
Some GPs described a diminished sense of responsi-
bility over prescribing decisions for people with SMI, and 
the potential side- effects of APs, partly because they did 
not initiate the medication:
I’m not sitting down and thinking I might make this 
patient into a diabetic. That isn’t really crossing my 
mind because that decision of prescribing has not 
been mine. (GP001)
Some GPs described being willing to continue to 
prescribe medication initiated by specialists, partly due to 
the perceived risk of making alterations:
Maybe we do sort of more easily just say ‘yes, contin-
ue’ to those sorts of medications that have been ini-
tiated by a specialist at some point than you would 
do about another medication that feels less risky to 
consider stopping potentially or changing. (GP007)
GPs reported that they would contact HCPs in 
secondary care if patients presented physical health prob-
lems linked to APs, rather than make changes in medica-
tion themselves:
I’d treat the underlying condition, you know, the di-
abetes, the cholesterol and address the weight. But 
if we thought it was due to the metabolic effects of 
the drugs, I’d involve the psychiatrist involved in their 
care. (GP004)
Another contested area of responsibility was identified 
around who should inform patients about side- effects 
of AP medications. Several GPs reported taking over 
prescribing responsibilities without meeting patients and 
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discussing side- effects, based on the assumption patients 
had been informed in secondary care.
I rely on the psychiatrist to have already informed 
[the patient]. So I don’t. You would expect them to 
have done that, he’s taking responsibility for asking 
that drug to be provided so…. (GP001)
Many HCPs in primary and secondary care believed the 
responsibility for prescribing APs should be shared but 
that this was not currently the case:
Ideally it should be partnership working, collabora-
tive working. I think primary care have an important 
role because…I think they need to be alert to un-
derstanding that if one of their patients is on anti-
psychotic medication, there are important physical 
parameters that they should be alert to…I think the 
responsibility very much falls to us as the prescribers 
of antipsychotic medication to at least cover those 
particular parameters and if then we detect abnor-
malities, whether it’s in the ECG or cholesterol or 
diabetes, then involve the GP with the next step in 
terms of treatment or assessment…But it does cause 
tension sometimes. (PS004)
The way forward: a collaborative approach
Collaboration between clinicians, services and patients 
was thought to be key in supporting people with SMI. This 
would include discussion about: identifying the need for 
a switch, multidisciplinary discussion, supporting patients 
to make an informed decision about whether to switch, 
and creating a monitoring plan within teams:
I think with the help and support of our team that is 
the major thing that can help us for the switching, be-
cause we’ve got quite a few staff, you know, like we’ve 
got supportive, we’ve got CPN, support workers, they 
are monitoring them…community pharmacists, so 
they can help us to make a decision switching so it’s 
like a team decision, it’s not only one person’s de-
cision and obviously the patient’s, the patient’s deci-
sion at the end. (PS003)
GPs suggested that they couldn’t offer this level of 
support to patient due to limited time and resources 
and this was a key reason for asking for support from 
secondary care:
If she’s really deteriorating she needs a team around 
her anyway and so…it’s not just about the drugs, it’s 
about giving her wider support and getting the key 
worker involved so I suppose I’d get them… I’d just 
want more help in general rather than just with med-
ication. (GP003)
Information sharing was felt to be crucial to supporting 
a switch of APs. HCPs in secondary care reported 
providing detailed information to GPs when handing 
over prescribing responsibility, including side- effects, 
risks and monitoring requirements:
And the GPs are prescribing we send them an ESCA 
with all the information about the side effects, the 
monitoring that’s required, what dosage the patient 
is on and you know what were the last tests done so 
the GPs can carry through from that. (PS009)
However, some GPs reported receiving scant infor-
mation when taking over prescribing; this left some 
GPs unsure about whose responsibility this was, what to 
monitor and how to use routinely collected data to inform 
clinical decisions.
They don’t really give us any guidance on when do 
we worry, so we are measuring it but we don’t… if we 
then identify it really high, we still don’t know what 
to do and if you ask us specifically they just sort of go, 
‘yeah, whatever…’ [laughs] so we’ve not had a huge 




This qualitative study suggests that HCPs prioritised the 
mental health needs of patients with SMI over their phys-
ical health needs when making decisions about treat-
ments, such as switching antipsychotics. Decisions that 
were felt to potentially jeopardise mental health stability 
and risk the onset or worsening of symptoms, were 
avoided, even at the detriment of increasing cardiomet-
abolic risk. Levels of awareness about the risk profiles 
of APs differed; HCPs in secondary care had a greater 
understanding than GPs. Switching was rarely considered 
a proactive option; more often switching was reactive to 
the development of a new physical health condition. In 
some situations, it took patients raising concerns about 
their physical health and linking this to APs for HCPs to 
consider switching. Responsibility for decision- making 
around APs was commonly deferred to specialist care. 
The need for better collaboration was highlighted but the 
fragmentation of care, poor communication and incon-
sistencies in information- sharing prevented this, which 
may lead to duplication or gaps between primary and 
secondary care.
Strengths and limitations
The study provides an in- depth exploration of the barriers 
and facilitators to switching APs in primary and secondary 
care. Data analysis was rigorous and involved researchers 
from different clinical and academic backgrounds. The 
concept of inductive thematic saturation guided data 
collection and analysis. Saturation was reached with GP 
and psychiatrist data. Recruitment of mental health nurses 
was challenging, as many declined due to workload and/
or did not perceive switching as part of their clinical remit 
(which in itself is an important finding); saturation could 
not therefore be achieved in data arising from this group. 
The sample was self- selected, therefore participating 
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clinicians may be more in favour of switching, although 
we were not able to assess this as treatment preferences 
were not explored. Psychiatrists and nurses were recruited 
from one mental health trust; further research is required 
to explore the themes reported in this paper in different 
geographic and service- level contexts. The research team 
attempted to recruit GPs working in localities where there 
was a blanket rule not to prescribe APs to explore barriers 
to collaborative working in the context of SMI, but no 
GPs agreed to be interviewed.
Comparison with existing literature
Almost all literature on switching APs focuses on strate-
gies for switching and pharmacological interactions or 
pharmacokinetics. This is the first study to examine the 
views of HCPs in switching APs, hence the comparison 
with existing literature is difficult.
Levels of knowledge about the risk profiles of APs 
contrasted sharply between HCPs in primary and 
secondary care with the latter evidencing far greater 
awareness. However, people with SMI have previously 
described a lack of acknowledgement from psychiatrists 
about the negative impacts of medication on their quality 
of life and physical health concerns.23 Patients value the 
importance of good physical health, but often feel over-
whelmed by comorbid health problems,24 and may feel 
powerless in decision- making about APs and consider 
APs to be the ‘least worst option’ despite problematic 
side- effects.23 HCPs in our study did not seem to engage 
patients in all aspects of AP decision- making, devaluing 
the insights that patients have.25 Exploration of patient 
perspectives on switching is needed to understand how 
shared decision- making can be achieved.
Switching presents one method to address physical 
health conditions in individuals with SMI. Other strate-
gies include lifestyle interventions, choosing lower risk 
APs at treatment initiation and prescribing medications 
to treat physical health conditions.10 16 Trial evidence 
of lifestyle interventions for people with SMI is poor 
for physical health outcomes and cost- effectiveness,8 9 
although a recent trial showed that an 18- month intensive 
intervention could reduce overall cardiovascular risk.26 
HCPs in our study reported continuing to promote life-
style advice first- line. Concerns about jeopardising mental 
health presented a barrier to switching; evidence for the 
effectiveness of lower risk APs suggests these concerns 
may be exaggerated11–13 and should be reconsidered 
given the potential to achieve physical health improve-
ments.15 The evidence on efficacy of APs27 and effects 
of APs on glucose levels28 clearly show that different APs 
have relatively small differences in efficacy for symptom 
management but significant differences for weight gain 
and metabolic side- effects.
A lack of clarity and consistency regarding where 
responsibility lies for identifying and managing phys-
ical problems in people with SMI remains a challenge.29 
Previous research has highlighted challenges facing GPs 
prescribing APs for older people with dementia due to 
a lack of appropriate clinical guidance to inform deci-
sions.30 A lack of collaboration between specialist mental 
health services and primary care have been reported else-
where as a key barrier to the management of people with 
SMI.31 Pedley et al25 call for mandated prescriber respon-
sibilities to ensure that the input from all stakeholders 
is valued in decisions about AP medication. Our study 
further reiterated barriers of communication, informa-
tion sharing and involvement of primary and secondary 
HCPs as part of multidisciplinary teams.
Implications for practice and future research
Given the limited evidence for brief lifestyle interven-
tions to reduce cardiometabolic risk for people with 
SMI, HCPs should consider physical health at every 
contact, and switching APs should be on the agenda 
before cardiometabolic complications emerge. Guidance 
is needed to inform HCPs about how to use routinely 
collected physical health data to inform decision- making 
about interventions. Prompts in medical record systems 
could alert HCPs about key data and/or high metabolic 
risks related to APs. Identifying HCP training needs 
and providing further education is required to support 
switching. Existing tools that support the assessment of 
cardiometabolic health in people with SMI, such as the 
Lester tool,32 could be put to better use. A multidisci-
plinary team approach is needed that comprises clear 
lines of responsibility for HCPs that places patients at the 
centre of decision- making. Resources should be available 
to patients about AP risk profiles to support dialogue 
with HCPs; pharmacists could also play an important role 
here. Future research should explore patient views on 
switching.
These qualitative insights could inform the develop-
ment of information and education resources for HCPs 
and patients and/or interventions (such as a switching 
protocol) for future evaluation and testing. Switching 
APs could offer a valuable means of responding to the 
widening mortality gap for people with SMI.
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